Publications by authors named "Jim Bush"

Claim this Profile
R
Results of a phase 1/2 study of cemdisiran in healthy subjects and patients with paroxysmal nocturnal hemoglobinuria.
Anna Gaya, Talha Munir, Alvaro Urbano-Ispizua, Morag Griffin, Jorg Taubel, Jim Bush

EJHaem· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects.
Dorothy Cheung, Alice Fong, Han Ting Ding, Christopher R Cabanski, Jianshuang Wang, Jim Bush

Pulm Pharmacol Ther· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2.
Wendy Holman, Wayne Holman, Stacy McIntosh, Wendy Painter, George Painter, Jim Bush

Trials· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of an extended-release peptide YY analogue for obesity: A randomized, placebo-controlled, phase 1 trial.
Tricia M-M Tan, James Minnion, Bernard Khoo, Laura-Jayne Ball, Reshma Malviya, Jim Bush

Diabetes Obes Metab· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2.
Wendy P Painter, Wayne Holman, Jim A Bush, Firas Almazedi, Hamzah Malik

Antimicrob Agents Chemother· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects.
Jim Bush, Kazuki Kawakami, Rafael Muniz

BMC Pharmacol Toxicol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of the Pharmacokinetics of Vilaprisan: Bioavailability, Excretion, Biotransformation, and Drug-Drug Interaction Potential.
Marcus-Hillert Schultze-Mosgau, Joachim Höchel, Olaf Prien, Torsten Zimmermann, Ashley Brooks, Jim Bush

Clin Pharmacokinet· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the safety profile of an electronic vapour product used for two years by smokers in a real-life setting.
Tanvir Walele, Jim Bush, Annelize Koch, Rebecca Savioz, Claire Martin

Regul Toxicol Pharmacol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel-group, phase I study in healthy subjects.
Tomohiko Harada, Darren Wilbraham, Guillemette de La Borderie, Shinsuke Inoue, Jim Bush

Br J Clin Pharmacol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitigation of Initial Cardiodynamic Effects of the S1P Receptor Modulator Ponesimod Using a Novel Up-Titration Regimen.
Pierre-Eric Juif, Matthias Hoch, Andrea Vaclavkova, Andreas Krause, Jim Bush

J Clin Pharmacol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised, parallel group study to evaluate the safety profile of an electronic vapour product over 12 weeks.
Ana S Cravo, Jim Bush, Girish Sharma, Rebecca Savioz, Claire Martin

Regul Toxicol Pharmacol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction of tendon adhesions following administration of Adaprev, a hypertonic solution of mannose-6-phosphate: mechanism of action studies.
Jason K F Wong, Anthony D Metcalfe, Richard Wong, Jim Bush, Chris Platt

PLoS One· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of interleukin-10 on cutaneous wounds and scars in humans of African continental ancestral origin.
Ingrid Kieran, Catherine Taylor, Jim Bush, Mark Rance, Karen So

Wound Repair Regen· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and development of avotermin (recombinant human transforming growth factor beta 3): a new class of prophylactic therapeutic for the improvement of scarring.
Nick L Occleston, Sharon O'Kane, Hugh G Laverty, Mark Cooper, David Fairlamb, Jim A Bush

Wound Repair Regen· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapies with emerging evidence of efficacy: avotermin for the improvement of scarring.
Jim Bush, Karen So, Tracey Mason, Nick L Occleston, Sharon O'Kane

Dermatol Res Pract· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Remote wound monitoring of chronic ulcers.
Sonja A Weber, Niall Watermann, Jacques Jossinet, J Anthony Byrne, Jonquille Chantrey, Jim Bush

IEEE Trans Inf Technol Biomed· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surgical instruments, sutures and suturing techniques.
Jim Bush, Ardeshir Bayat

Br J Hosp Med (Lond)· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis